Non-invasive prenatal testing – new possibilities on the horizon and old problems
- 1Jena University Hospital Institute of Human Genetics Am Klinikum 1 07747 Jena Germany
Abstract
Non-invasive prenatal testing (NIPT) is a screening method that accesses placenta-derived DNA. Contrary to its name, no foetal DNA is tested here, despite the fact that it is often referred to as a test of ‘free foetal DNA’. NIPT is available in at least five different technical variants and can test for aneuploidies of chromosomes 13, 18 and 21, with or without testing the sex chromosomes. It can also test all chromosomes for aneuploidy, although polyploidy is only accessible with a single nucleotide polymorphism (SNP)-based test system. It can also check for targeted microdeletion/microduplication syndrome critical regions. Among others, as NIPT uses placental DNA, a certain rate of false-positive and false-negative results is to be expected in the case of copy number variation detection. For some years now, existing commercial NIPT variants have been expanded to include single-gene-mutation-oriented testing. Here, foeto-placental divergence seems to play a minor role, while distinguishing maternal and placenta-derived cell-free DNA remains challenging. This article reviews the milestones of NIPT and its current developments, focusing on the challenges of incorporating this approach into existing prenatal care schemes and the situation in Germany.
Related
- Non-Invasive Prenatal Testing in Donor-Oocyte Pregnancies: Biological Determinants, Algorithmic Limitations and Clinical Implications
- Prenatal diagnostic outcomes and positive predictive values in 1,326 pregnancies with high-risk non-invasive prenatal testing results
- Haplotype-based non-invasive prenatal testing of F8 complex rearrangement via targeted capture sequencing of maternal plasma.
- Smelling a RAT: a reanalysis of suspected common aneuploidy results for the presence of rare autosomal trisomies (RATs) in non-invasive prenatal testing
- A Conceptual Roadmap toward Informed Prenatal Genetic Screening and Diagnostic Testing: A Qualitative Study
BibTeX
@article{weise2026noninvasive,
title = {{Non-invasive prenatal testing – new possibilities on the horizon and old problems}},
author = {Anja Weise and Thomas Liehr},
journal = {Medizinische Genetik},
year = {2026},
month = nov,
doi = {10.1515/medgen-2026-3028},
url = {https://doi.org/10.1515/medgen-2026-3028},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Non-invasive prenatal testing – new possibilities on the horizon and old problems
AU - Anja Weise
AU - Thomas Liehr
PY - 2026
DA - 2026/11/06
JO - Medizinische Genetik
DO - 10.1515/medgen-2026-3028
UR - https://doi.org/10.1515/medgen-2026-3028
AB - Non-invasive prenatal testing (NIPT) is a screening method that accesses placenta-derived DNA. Contrary to its name, no foetal DNA is tested here, despite the fact that it is often referred to as a test of ‘free foetal DNA’. NIPT is available in at least five different technical variants and can test for aneuploidies of chromosomes 13, 18 and 21, with or without testing the sex chromosomes. It can also test all chromosomes for aneuploidy, although polyploidy is only accessible with a single nucleotide polymorphism (SNP)-based test system. It can also check for targeted microdeletion/microduplication syndrome critical regions. Among others, as NIPT uses placental DNA, a certain rate of false-positive and false-negative results is to be expected in the case of copy number variation detection. For some years now, existing commercial NIPT variants have been expanded to include single-gene-mutation-oriented testing. Here, foeto-placental divergence seems to play a minor role, while distinguishing maternal and placenta-derived cell-free DNA remains challenging. This article reviews the milestones of NIPT and its current developments, focusing on the challenges of incorporating this approach into existing prenatal care schemes and the situation in Germany.
SN - 0936-5931
SN - 1863-5490
ER -